Effect of methylprednisolone on lung function after minimally invasive heart valve surgery under fast channel anesthesia

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400084270

Enrollment

Unknown

Registered

2024-05-14

Start date

2023-02-02

Completion date

Unknown

Last updated

2024-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Valvular heart disease

Interventions

A group:methylprednisolone 4mg/kg

B group :methylprednisolone 2mg/kg

C group:saline

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Patients aged 18-70 years. (2) American Society of Anesthesiologists (ASA) Grade I-III (3) NYHA cardiac function Grade III and below (4) There were no lung lesions before surgery, and oxygenation index: PaO2(partial arterial oxygen pressure)/FiO2(oxygen concentration)>300 mmHg

Exclusion criteria

Exclusion criteria: (1) Preoperative renal insufficiency (creatinine >1.6 mg/dL), renal failure with oliguria or anuria, hemodialysis required (2) Liver dysfunction (bilirubin >3mg/dL) (3) Planned intraoperative cryogenic circulatory arrest (4) Known allergy to methylprednisolone and contraindications to nervous tissue (5) Existing clotting or bleeding disorders. (6) Pregnancy, emergency surgery (7) The patient refused to cooperate

Design outcomes

Primary

Measure	Time frame
Pulmonary function index;Indicators of inflammatory factors;Clotting and thrombosis related indicators;	—

Secondary

Measure	Time frame
Paroxysmal drug use;postoperative complication;	—

Countries

China

Contacts

Public ContactYan Meijuan

Zhejiang Provincial People‘s Hosipital

1514018695@qq.com+86 139 5711 6714

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026